MPH’s Cooper leads sickle cell patient prescribed medication effort for Vanderbilt
Vanderbilt University Medical Center is part of a 6-year, $4.4 million grant from the National Institutes of Health to improve the use of prescribed medication by sickle cell patients. Funded by the National Heart, Lung and Blood Institute (Grant No. 1U01HL133996-01), the new Sickle Cell Disease Implementation Program includes researchers from St. Jude Children’s Research Hospital, the University of Memphis, Methodist University Hospital, Baptist Memorial Hospital and Vanderbilt.
The team from Vanderbilt, led by William Cooper, M.D., M.P.H., Cornelius Vanderbilt Professor of Pediatrics and Health Policy, will use administrative health care insurance data from Medicare, TennCare and a commercial payer to measure the use and impact of hydroxyurea for children and adults in the state.